Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Hematologists who Treat Lymphoma

March 11, 2008
Avastin: Not for every one with breast cancer, but benefit is real for selected patients.
By a GLG Expert Contributor
Analysis of: The High Cost of a Cancer Drug (www.nytimes.com)
FDA's approval of Genentech's Avastin is backed both by efficacy data and aggressive political activism. Extension of PFS by almost 6 months and shrinking large tumors, thus improving quality of life, are tangible and real beneficial effects. Avastin was already being prescribed off-label. The approval...
March 10, 2008
Amgen and J & J: FDA adding insult to injury #5
By a GLG Expert Contributor
Analysis of: FDA Adds More Black-Box Warnings To Anemia Drugs From Amgen, J&J (online.wsj.com)
The FDA is now warning of increased death & tumor growth in breast and cervical cancer patients.
March 10, 2008
Wouldn't you want 5 1/2 more months if you had metastatic breast cancer?
By a GLG Expert Contributor
Analysis of: The High Cost of a Cancer Drug (www.nytimes.com)
This editorial is questioning the use of this expensive agent in patients with metastatic breast cancer when it only increases time to progression 5.5 months.
March 10, 2008
Teva's generic Irinotecan will gradually cut into the brand name use
By a GLG Expert Contributor
Analysis of: Teva Announces Approval Of Generic Camptosar(R) (www.pipelinereview.com)
Pfizer's Irinotecan ( CPT-11) is mostly used in colorectal cancer with some limited use in sarcomas, glioblastoma multiforme, and other solid tumors. Teva's generic compound is expected to be cheaper, and with current economic situation, may be mandated by third party payers to cut costs, and this will...
March 10, 2008
AS1409 : Not so novel drug in an already crowded market
By a GLG Expert Contributor
Analysis of: Antisoma starts phase I clinical trial of AS1409 in renal cancer and melanoma (www.pipelinereview.com)
Antisoma's AS 1409 has just entered a clinical phase I trial for patients with advanced melanoma and renal cancer. While efficacy results are years ago, this "immunotherapy" will be competing with many approved targeted agents in renal cancer ( Sutent, Nexavar, Torisel) and with many other immunotherapeutic...
March 7, 2008
American Cancer Society is promoting money in CaCa analysis?
By a GLG Expert Contributor
Analysis of: Two Tests Added to Recommended List to Prevent or Detect Colorectal Cancer (www.nytimes.com)
Virtual Colonoscopy and stool analysis for DNA alterations for colon cancer, are being recommended for screening.
March 6, 2008
Heparin: Unfractionated Heparin, more expensive, less effective and dangerous compared to low molecular weight varieties
By a GLG Expert Contributor
Analysis of: Acute Pulmonary Embolism (content.nejm.org)
     With recent developments in preparation of unfractionated heparins (http://www.nytimes.com/2008/03/06/health/06heparin.html?_r=1&ref=health&oref=slogin) not only are the LMWH varieties more effective as well as cheaper when all of the co factors are included, they...
March 5, 2008
Cholesterol lowering: to advertise or not???
By a GLG Expert Contributor
Analysis of: Drug Pitchmen: Actor, Doctor or Pfizer’s Option (www.nytimes.com)
"Celebrity" advertisements of percription drugs are disingenuous?
March 3, 2008
Teva Camptosar: significance?
By a GLG Expert Contributor
Analysis of: Teva Announces Approval Of Generic Camptosar(R) (www.pipelinereview.com)
Camptosar is being made in Israel I would imagine, and the price differential compared to Pfizer's brand name drug is????
March 3, 2008
"RECORD" would bring record number of approved targted agents for renal cancer
By a GLG Expert Contributor
Analysis of: Novartis Late-State Cancer Trial Is Stopped Early After Meeting Goal (online.wsj.com)
the "Record" trial showed that Novatis' m-Tor inhibitor, everolimus improved progression free survival as compared to placebo in patients with advanced renal cancer who failed several other therapies including Avastin ( Genentech), Nexavar ( Bayer) and/or Sutent ( Pfizer). With The field of targeted...

Previous Page : 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next171 to 180 of 693

Analytics


Generated at 2009-01-07T13:00:17.563